
Acquisition - November 2, 2016
Karo Pharma acquires BioPhausia
Medivir has entered into an agreement with Karo Pharma regarding the sale of its subsidiary BioPhausia. The purchase price will be SEK 908 million on a cash and debt free basis, including a normalized working capital an the transaction is expected to close by mid-December 2016. As previously communicated the Board of Directors of Medivir tasked […]